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124a Sunday, February 21, 2010study aimed to assess whether another Cl- channel blocker, anthracene-9-car-
boxylic acid (A9C), is also affected by channel phosphorylation. A9C blocks
IClCa at positive potentials but paradoxically stimulates the inward IClCa tail af-
ter repolarization to negative potentials (Piper & Greenwood, Br J Pharmacol
138: 31-38, 2003). IClCa was evoked by pipette solutions containing 500 nM
free Ca2þ with or without 5 mM ATP to alter the state of phosphorylation.
Although A9C (1-500 uM) dose-dependently blocked steady state IClCa at
potentials positive to 0 mV in all cell groups, its maximal effect and sensitivity
to voltage were enhanced in cells dialyzed with 0 vs. 5 mM ATP. For example,
maximal block by 100 uM A9C was 35 and 73%, and V0.5 was 110 and 67 mV,
in cells with 5 vs 0 ATP, respectively. A9C enhanced IClCa tail at 80 mV by
causing a negative shift in voltage-dependence in both cell groups, with a larger
shift occurring in cells dialyzed with 5 mM ATP. Interestingly, 100 but not
500 uM A9C stimulated steady-state ICl(Ca) at potentials < 0 mV in cells dia-
lyzed with 0 ATP, a potential range where ICl(Ca) was unaffected in myocytes
dialyzed with 5 mM ATP. As with NFA, the complex actions of A9C on IClCa
are influenced by the state of channel phosphorylation and we propose the ex-
istence of at least two binding sites with different affinities for A9C.
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The large conductance Ca2þ-activated Kþ (BK) channels play an important role
in the regulation of vascular tone in response to changes in intracellular meta-
bolic status and Ca2þ homeostasis. Angiotensin II (Ang II)-mediated c-Src acti-
vation is known to inhibit the activities of BK channels. Recently, trafficking of
theAng II type I receptor (AT1R) into caveolaewas shown to be essential forAng
II signaling and activation of c-Src. We found that BK channels and the AT1R
signaling complex are colocalized in the caveolae of vascular smooth muscle
cells (VSMC). In this study, we examined the role of caveolae in the Ang
II-mediated modulation of BK channels by co-expressing hSlo channels,
AT1R, caveolin-1, and c-Src in HEK293 cells. Immunoblot analysis confirmed
that hSlo and AT1R were co-precipitated by anti-caveolin-1 antibody only in
cells co-transfected with caveolin-1, but not in those without caveolin-1, sug-
gesting that hSlo, AT1R, and caveolin-1 were physically associated. Exposure
to Ang II (2 mM) inhibited the hSlo current density by 32.752.8 %, and the
Ang II effect was blocked by Losartan (2 mM) with only 1.257.8 % current
inhibition. However, in cells coexpressing hSlo, c-Src, caveolin-1, and the
AT1R F233A mutant, which abolished its interaction with the caveolin-1 scaf-
folding domain, exposure to Ang II produced only 6.053.7% hSlo current inhi-
bition suggesting that caveolae targeting of AT1R is crucial for Ang II-mediated
BK channel regulation. These results were confirmed by experiments using
mouse VSMC. Ang II produced 40% inhibition of BK currents in cells from
wt mouse but had no effect on those from cav-1(-/-) animals. Hence, transloca-
tion of AT1R into caveolae upon agonist activation represents a critical step in
Ang II regulation of BK channels and vascular function.
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Cardiovascular sensitivity to anesthetics has been linked to the renin-angioten-
sin system (RAS), and it is thought to be related to the differences in cardio-
vascular collapse observed between SS and BN rats. In a previous study we
found that congenics carrying the BN renin allele (reninþ) in the SS back-
ground had the same cardiovascular sensitivity and low BK channel activity as
BN rats. On the other hand, congenics carrying the SS renin allele (renin-) dis-
played high BK activity and behaved like SS rats, suggesting that RSA could
be involved in differential responses. To test this hypothesis, the inhibition of
BK channel by angiotensin II (AngII, 100 nM) was evaluated in four strains.
Activity of BK was monitored from isolated mesenteric arterial smooth mus-
cle cells of SS and BN rats, and reninþ and renin- congenic rats in the cell-
attached mode at þ80 mV Em and in symmetrical 150 mM Kþ. Blockade by
paxilline (1 mM) confirmed identity of BK channel. Similar to findings from
our previous study, in the cell-attached mode the probability of BK channel
opening (Po) was different between SS (high Po) and BN (lower Po). The
BK activity of renin2- resembled that of SS, whereas BK activity of reninþ
matched BN. AngII had a greater inhibitory effect on channel Po in BN
(55þ7%) and reninþ (94þ2%) strains than in SS (9þ6%) and renin-(7þ2%) strains. Impaired renin expression and impaired RAS are associated
with lower sensitivity of BK to inhibition by AngII in SS than in BN rats. The
fact that reninþ and renin- strains follow a similar pattern appears to support
this conclusion.
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MaxiK channel, composed of the pore-forming a (MaxiKa) and regulatory b1
subunits, controls vascular tone via the activation or inhibition of its pore con-
ducting activity. Thromboxane A2 receptor (TPR), a G-protein coupled recep-
tor, induces potent vasoconstriction mediated by its agonist, thromboxane A2.
Previously, we demonstrated that U46619, the stable analogue of thromboxane
A2 inhibits MaxiK channel in vascular smooth muscle cell contributing to
U46619-induced vasoconstriction. In this study, we report that this inhibition
is reversed by nanomolar dehydrosoyasaponin I (DHS-I), a pharmacological
tool that indicates MaxiKa and b1 association and functional coupling. The re-
versing effect of DHS-I indicated that the MaxiK channels inhibited by U46619
could be coupled with regulatory b1 subunits. Co-immunoprecipitation and
double immunolabeling in co-expressing cells showed that TPR form a complex
with b1 on the plasma membrane. To identify the interacting sites in b1 respon-
sible for TPR-b1 complex formation, we prepared serial carboxyl-terminal
deletions of b1 and analyzed their interaction properties with TPR in co-
immunoprecipitation experiments. b1 lacking amino acids 103-191 reduces
the TPR-b1 association by 44 5 14% (p<0.01), while deletion of residues
73-191 completely reduces the TPR-b1 interaction, suggesting that amino acids
73 to 191 predominantly contribute to the TPR-b1 interaction. To further inves-
tigate how b1 regulates TPR-MaxiKa functional coupling, inside-out patch
clamp experiments were performed in HEK293T cells expressing TPRþMax-
iKa þ/- b1 subunit. We found that the b1 subunit reduces U46619-induced
MaxiKa inhibition in a dose-dependent manner. In summary, b1 interacts
with TPR forming a tripartite complex with MaxiKa and opposes to TPR ag-
onist-induced MaxiK channel inhibition serving as a buffer to vasoconstriction.
Thus, in pathological situations like hypertension or aging where b1 expression
is compromised the TPR-MaxiK complex would induce severe vasoconstric-
tion. Supported by NIH and AHA.
648-Pos
Kca3.1 Blockers as Potential New Drugs for the Prevention of Renal
Fibrosis and Chronic Allograft Rejection
Heike Wulff1, Yi-Je Chen1, Sonja Schrepfer2, Ralf Ko¨hler3.
1University of California, Davis, CA, USA, 2University Heart Center,
Hamburg, Germany, 3University of Southern Denmark, Odense, Denmark.
The calcium-activated potassium channel KCa3.1 is critically involved in the
proliferation and migration of T cells, macrophages, dedifferentiated vascular
smooth muscle cells and fibroblasts by regulating membrane potential and cal-
cium influx. KCa3.1 has therefore been suggested as a potential therapeutic tar-
get for various diseases where activation and excessive proliferation of one or
more of these cell types is involved in the pathology. Using the selective small
molecule KCa3.1 blocker TRAM-34 as a pharmacological tool compound we
previously demonstrated that KCa3.1 blockade prevents restenosis in both
rats and pigs and reduces atherosclerosis development in ApoE-/- mice. We
now used two models of chronic allograft rejection and one model of kidney
fibrosis to evaluate whether KCa3.1 blockers might also be useful for the
prevention of transplant rejection and fibrotic kidney changes. In a murine
model of obliterative airway disease, where tracheas from CBA mice were
heterotopically transplanted into the greater omentum of C57Bl6 mice, both
genetic deficiency or pharmacological blockade of KCa3.1 with TRAM-34
reduced luminal obliteration from 9257% to 60529% or 61528% (n ¼ 6
per group). We further performed orthotopic aortic transplantations in the
PVG-to-ACI rat model and evaluated chronic allograft vasculopathy after
120 days. TRAM-34 at 10 mg/kg (35%) and 40 mg/kg (60%) dose-
dependently reduced chronic aortic luminal obliteration. Genetic disruption
of KCa3.1 and pharmacological blockade also reduced fibrotic marker expres-
sion, chronic tubulointerstitial damage, collagen deposition and alphaSMA(þ)
cells in kidneys following unilateral ureteral obstruction in mice. Taken to-
gether, our findings suggest that KCa3.1 channels are involved in the pathology
of obliterative airway disease, chronic allograft vasculopathy and fibrotic
kidney disease.
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